Patents by Inventor Carl H. June

Carl H. June has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified Monocytes/Macrophage Expressing Chimeric Antigen Receptors and Uses Thereof
    Publication number: 20220002377
    Abstract: The present invention includes methods and compositions for treating cancer, whether a solid tumor or a hematologic malignancy. By expressing a chimeric antigen receptor in a monocyte, macrophage or dendritic cell, the modified cell is recruited to the tumor microenvironment where it acts as a potent immune effector by infiltrating the tumor and killing the target cells. One aspect includes a modified cell and pharmaceutical compositions comprising the modified cell for adoptive cell therapy and treating a disease or condition associated with immunosuppression.
    Type: Application
    Filed: September 16, 2021
    Publication date: January 6, 2022
    Inventors: Saar GILL, Michael KLICHINSKY, Carl H. JUNE
  • Modified Monocytes/Macrophage Expressing Chimeric Antigen Receptors and Uses Thereof
    Publication number: 20220002375
    Abstract: The present invention includes methods and compositions for treating cancer, whether a solid tumor or a hematologic malignancy. By expressing a chimeric antigen receptor in a monocyte, macrophage or dendritic cell, the modified cell is recruited to the tumor microenvironment where it acts as a potent immune effector by infiltrating the tumor and killing the target cells. One aspect includes a modified cell and pharmaceutical compositions comprising the modified cell for adoptive cell therapy and treating a disease or condition associated with immunosuppression.
    Type: Application
    Filed: September 16, 2021
    Publication date: January 6, 2022
    Inventors: Saar GILL, Michael KLICHINSKY, Carl H. JUNE
  • Altering gene expression in modified T cells and uses thereof
    Patent number: 11208661
    Abstract: The present invention relates to compositions and methods for generating a modified T cell with a nucleic acid capable of downregulating endogenous gene expression selected from the group consisting of TCR ? chain, TCR ? chain, beta-2 microglobulin and FAS further comprising a nucleic acid encoding a modified T cell receptor (TCR) comprising affinity for a surface antigen on a target cell or an electroporated nucleic acid encoding a chimeric antigen receptor (CAR). Also included are methods and pharmaceutical compositions comprising the modified T cell for adoptive therapy and treating a condition, such as an autoimmune disease.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: December 28, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Yangbing Zhao, Jiangtao Ren, Xiaojun Liu, Carl H. June
  • Altering gene expression in modified T cells and uses thereof
    Patent number: 11203758
    Abstract: The present invention relates to compositions and methods for generating a modified T cell with a nucleic acid capable of downregulating endogenous gene expression selected from the group consisting of TCR ? chain, TCR ? chain, beta-2 microglobulin and FAS further comprising a nucleic acid encoding a modified T cell receptor (TCR) comprising affinity for a surface antigen on a target cell or an electroporated nucleic acid encoding a chimeric antigen receptor (CAR). Also included are methods and pharmaceutical compositions comprising the modified T cell for adoptive therapy and treating a condition, such as an autoimmune disease.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: December 21, 2021
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Yangbing Zhao, Jiangtao Ren, Xiaojun Liu, Carl H. June
  • USE OF THE CD2 SIGNALING DOMAIN IN SECOND-GENERATION CHIMERIC ANTIGEN RECEPTORS
    Publication number: 20210371495
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain, a transmembrane domain, a CD2 signaling domain, and a CD3 zeta signaling domain. The invention also includes incorporating CD2 into the CAR to alter the cytokine production of CAR-T cells in both negative and positive directions.
    Type: Application
    Filed: August 5, 2021
    Publication date: December 2, 2021
    Inventors: Carl H. June, John Scholler, Avery D. Posey, JR.
  • Tn-MUC1 Chimeric Antigen Receptor (CAR) T Cell Therapy
    Publication number: 20210338733
    Abstract: Various TnMUC1-specific chimeric antigen receptors (CARs), nucleic acids encoding the same, and methods of using the same, are provided. Compositions and methods comprising a TnMUC1-specific CAR for treating MUC1-associated cancer in a subject in need thereof are provided.
    Type: Application
    Filed: July 8, 2021
    Publication date: November 4, 2021
    Inventors: Avery D. Posey, Carl H. June
  • Car-expressing cells against multiple tumor antigens and uses thereof
    Patent number: 11161907
    Abstract: The invention provides compositions and methods for treating cancer by using immune effector cells (e.g., T cells, NK cells) engineered to conditionally express an agent which enhances the immune effector response of an immune effector cell that expresses a Chimeric Antigen Receptor (CAR). The conditional agents described herein include agents that target a cancer associated antigen, e.g., a CAR, agents that inhibit one or more checkpoint inhibitors of the immune response, and a cytokine.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: November 2, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Carl H. June, Daniel J. Powell, Jr.
  • CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell
    Patent number: 11149076
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with one or more B-cell inhibitors, e.g., inhibitors of one or more of CD10, CD20, CD22, CD34, CD123, FLT-3, ROR1, CD79b, CD179b, or CD79a. The disclosure additionally features novel antigen binding domains and CAR molecules directed to CD20 and CD22, and uses, e.g., as monotherapies or in combination therapies. The invention also provides kits and compositions described herein.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: October 19, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Hans Bitter, Jennifer Mary Bordeaux, Barbara Brannetti, Jennifer Brogdon, Naveen Kumar Dakappagari, Saar Gill, Steven Highfill, Lu Huang, Carl H. June, Ju Young Kim, Ming Lei, Na Li, Andreas Loew, Elena Orlando, Marco Ruella, Thai Tran, Jimin Zhang, Li Zhou
  • ENHANCED ANTIGEN PRESENTING ABILITY OF RNA CAR T CELLS BY CO-INTRODUCTION OF COSTIMULATORY MOLECULES
    Publication number: 20210317183
    Abstract: The invention provides T cells comprising nucleic acid sequence encoding a chimeric antigen receptor and a nucleic acid sequence encoding an enhancer of T cell priming, compositions including the T cells, and methods of using the T cells to treat diseases associated with the expression of disease-associated antigens.
    Type: Application
    Filed: April 22, 2021
    Publication date: October 14, 2021
    Inventors: Yangbing Zhao, Devon J. Shedlock, Carl H. June, Xiaojun Liu
  • TREATMENT OF CANCER USING HUMANIZED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
    Publication number: 20210284752
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19. The invention also relates to chimeric antigen receptor (CAR) specific to CD19, vectors encoding the same, and recombinant T cells comprising the CD19 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD19 binding domain.
    Type: Application
    Filed: December 23, 2020
    Publication date: September 16, 2021
    Inventors: Jennifer Brogdon, Carl H. June, Andreas Loew, Marcela Maus, John Scholler
  • INDUCIBLE REGULATORY T-CELL GENERATION FOR HEMATOPOIETIC TRANSPLANTS
    Publication number: 20210275650
    Abstract: The present invention provides methods and compositions for converting non-Tregs into Tregs. The converted Tregs are referred to as inducible Tregs (iTregs). The iTregs are useful for preventing, suppressing, blocking or inhibiting an immune response. For example the iTregs are useful for preventing rejection of a transplanted tissue in a human or other animal host, or protecting against graft vs host disease. The iTregs can also be used to treat autoimmune diseases.
    Type: Application
    Filed: December 24, 2020
    Publication date: September 9, 2021
    Inventors: James L. Riley, Carl H. June, Bruce R. Blazar, Keli Hippen
  • Tn-MUC1 chimeric antigen receptor (CAR) T cell therapy
    Patent number: 11090336
    Abstract: Various TnMUC1-specific chimeric antigen receptors (CARs), nucleic acids encoding the same, and methods of using the same, are provided. Compositions and methods comprising a TnMUC1-specific CAR for treating MUC1-associated cancer in a subject in need thereof are provided.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: August 17, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Avery D. Posey, Carl H. June
  • METHODS FOR IMPROVING THE EFFICACY AND EXPANSION OF IMMUNE CELLS
    Publication number: 20210246423
    Abstract: The invention provides methods of making immune effector cells (e.g., T cells, NK cells) that can be engineered to express a chimeric antigen receptor (CAR), compositions and reaction mixtures comprising the same, and methods of treatment using the same.
    Type: Application
    Filed: September 18, 2020
    Publication date: August 12, 2021
    Inventors: Felipe Bedoya, Saba Ghassemi, Carl H. June, Omkar U. Kawalekar, Bruce L. Levine, Jan J. Melenhorst, Michael C. Milone, Daniel J. Powell, Jr., Zoe Zheng
  • Anti-BCMA chimeric antigen receptor
    Patent number: 11084880
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of BCMA. The invention also relates to chimeric antigen receptor (CAR) specific to BCMA vectors encoding the same, and recombinant T cells comprising the BCMA CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a BCMA binding domain.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: August 10, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Eugene Choi, Hilmar Erhard Ebersbach, David Jonathan Glass, Heather Huet, Carl H. June, Joan Mannick, Michael C. Milone, Leon Murphy, Gabriela Plesa, Celeste Richardson, Marco Ruella, Reshma Singh, Yongqiang Wang, Qilong Wu
  • USE OF INHIBITORY CHIMERIC RECEPTORS TO PREVENT T CELL-INDUCED BLOOD BRAIN BARRIER DAMAGE
    Publication number: 20210230246
    Abstract: Neurotoxicity associated with CD19-targeted CAR-T therapy is reduced by including an inhibitory CAR (iCAR) in the CAR-T cell, wherein the iCAR specifically recognizes an antigen specific for or associated with neurovascular mural cells (e.g. pericytes or vSMC).
    Type: Application
    Filed: January 14, 2021
    Publication date: July 29, 2021
    Inventors: Avery Posey, Carl H. June, Denis Migliorini, Howard Chang, Ansuman Satpathy, Kevin Parker
  • THERAPEUTIC REGIMENS FOR CHIMERIC ANTIGEN RECEPTOR (CAR)- EXPRESSING CELLS
    Publication number: 20210177896
    Abstract: The invention provides a method of treating an adult subject having a hematological cancer, comprising administering to the subject selected dosage regimens comprising a plurality of immune effector cells expressing a CAR molecule.
    Type: Application
    Filed: June 2, 2017
    Publication date: June 17, 2021
    Inventors: David L. Porter, Noelle Frey, Carl H. June, Simon Lacey, Fang Chen, Jan J. Melenhorst, Tetiana Taran, Karen Thudium Mueller, Patricia Wood, Yiyun Zhang
  • Modified monocytes/macrophage expressing chimeric antigen receptors and uses thereof
    Patent number: 11034749
    Abstract: The present invention includes methods and compositions for treating cancer, whether a solid tumor or a hematologic malignancy. By expressing a chimeric antigen receptor in a monocyte, macrophage or dendritic cell, the modified cell is recruited to the tumor microenvironment where it acts as a potent immune effector by infiltrating the tumor and killing the target cells. One aspect includes a modified cell and pharmaceutical compositions comprising the modified cell for adoptive cell therapy and treating a disease or condition associated with immunosuppression.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: June 15, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Saar Gill, Michael Klichinsky, Carl H. June
  • Effective targeting of primary human leukemia using anti-CD123 chimeric antigen receptor engineered T cells
    Patent number: 11028177
    Abstract: The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (AML) and B-cell acute lymphoid leukemia (B-ALL). The invention also relates to at least one chimeric antigen receptor (CAR) specific to CD123, vectors comprising the same, and recombinant T cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD123 binding domain. The invention also includes methods of bone marrow ablation for use in treatments necessitating bone marrow reconditioning or transplant.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: June 8, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Jennifer Brogdon, Saar Gill, Carl H. June, Michael D. Kalos, Andreas Loew, John Scholler
  • Enhanced antigen presenting ability of RNA CAR T cells by co-introduction of costimulatory molecules
    Patent number: 11028143
    Abstract: The invention provides T cells comprising nucleic acid sequence encoding a chimeric antigen receptor and a nucleic acid sequence encoding an enhancer of T cell priming, compositions including the T cells, and methods of using the T cells to treat diseases associated with the expression of disease-associated antigens.
    Type: Grant
    Filed: January 21, 2015
    Date of Patent: June 8, 2021
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Yangbing Zhao, Devon J. Shedlock, Carl H. June, Xiaojun Liu
  • ICOS critically regulates the expansion and function of inflammatory human Th17 cells
    Patent number: 11001805
    Abstract: The invention includes compositions and methods for generating and expanding therapeutic Th17 cells. The invention includes contacting T cells with a composition comprising a first agent that is capable of providing a primary activation signal to T cells and a second agent that is capable of activating ICOS on T cells in the presence of Th-17 polarizing agents.
    Type: Grant
    Filed: May 22, 2018
    Date of Patent: May 11, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: James L. Riley, Chrystal Paulos, Carl H. June, Bruce L. Levine